Each December, an impressive cohort of breast cancer researchers gathers for the San Antonio Breast Cancer Symposium (SABCS), one of the largest breast cancer meetings in the world. Nestled between the holiday lights bedecking...
The FDA has approved pirtobrutinib for patients with heavily pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca) for the treatment...
FDA announces investigation into CAR T-cell therapy, and precision therapies are not available for most cancer diagnoses.
Ancient Greek physician Hippocrates considered the human body to be a system composed of four balanced fluids, or “humours.” The theory has long been supplanted, but contemporary oncology has brought body fluids back into...
Evidence grows that some people with HER2-positive breast cancer may do well on HER2-targeted therapy alone.
The FDA has approved nirogacestat for the treatment of noncancerous but painful growths called desmoid tumors. The U.S. Food and Drug Administration (FDA) has approved nirogacestat (Ogsiveo) for adult patients with desmoid tumors that...
With a five-year survival rate of only 12.5%, any progress toward new therapeutic approaches for pancreatic cancer is welcomed by patients and their families. At present, increasingly complex chemotherapy regimens offer only marginal improvements...
Low rates of germline genetic testing in cancer patients means information that could affect treatment isn’t available.
The FDA has approved enzalutamide for non-metastatic prostate cancer that is sensitive to antiandrogen therapy. The U.S. Food and Drug Administration (FDA) has approved enzalutamide (Xtandi) for the treatment of non-metastatic castration-sensitive prostate cancer...
The FDA has approved capivasertib for the treatment of breast cancers with certain mutations. The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap), in combination with fulvestrant (Faslodex), for the treatment of...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More